Creative Proteomics Cytokine Announces Cytokine Systemic Lupus Erythematosus Cytokines Assay Solutions

Ivan Chen
2 min readApr 20, 2022

Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative proteomics recently announced high sensitivity and wide detection range quantitative detection for systemic lupus erythematosus related cytokines and proteins through a variety of technologies.

Systemic lupus erythematosus is a typical systemic autoimmune disease characterized by the loss of autoimmune tolerance and the production of high levels of autoreactive antibodies against autoantigens, which leads to organ damage. This process involves a variety of cytokines. In human and mouse model systems, long-term expression of CD40L in lupus T cells may lead to excessive B cell activation, which in turn leads to the pathogenesis of the disease.

Creative Proteomics’s Luminex cytokine detection platform can detect the following cytokines involved in systemic lupus erythematosus:

(1) IL-6, IL-10, IL-12, IL-18, IFN-γ all suggest that the expression level of SLE will change to varying degrees during the development of SLE. IFN-γ inhibits the differentiation of Th0 to Th2. IL-4 and IL-10 inhibit the differentiation of Th0 to Th1. Cytokines secreted by mononuclear macrophages such as IL-12 and IL-18 also have a regulatory effect on Th1/Th2 differentiation.

(2) The B lymphocyte stimulation (BLyS) factor is a new member of the TNF ligand superfamily. It has strong proliferation, differentiation and antibody secretion effects on B cells, and plays an important role in the pathological process of SLE. TGF-β expression levels in SLE patients’ serum and urine are abnormal, suggesting that it could be a potential therapeutic target.

(3) TNF-α is a multifunctional pleiotropic cytokine in the immune system. It can not only promote the development of autoimmune inflammation, but also slow down the process of inflammation. It is an effective therapeutic target. For the treatment of SLE, a number of therapeutic TNF-α inhibitors have been developed.

“We mainly use the Luminex cytokine detection platform, which uses fluorescently encoded microspheres with specific antibodies to different target molecules. The different microspheres can be combined freely to a certain extent, so that up to 100 analytes can be tested multiple times simultaneously in a single experiment,” stated Creative Proteomics’s Product Manager.

“Creative Proteomics also uses flow cytometry (FACS analysis) and enzyme-linked immunosorbent assay (ELISA) to perform simultaneous quantitative detection of cytokines related to systemic lupus erythematosus disease with higher sensitivity and a wider detection range,” he added.

About Creative Proteomics

Creative Proteomics is an innovative contract research organization that focuses on using advanced equipment platforms and optimized detection technology to help researchers around the world reduce time and costs. The company has a proprietary laboratory information management system to strengthen laboratory quality monitoring and quality management to ensure the efficiency and security of customer data.